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Id1, which belongs to the Id family of helix-loop-helix transcription factors has been most associated with tumor progression and
metastatsis; however, its signiﬁcance in lung cancers has not been extensively explored. Here we seek to evaluate the expression
of Id1 in a pilot study of nonsmall-cell lung cancers (NSCLCs) and determine its diagnostic and functional signiﬁcance in these
tumors. Paired normal and malignant lung tissues as well as a panel of NSCLC primary tumors and cell lines were evaluated for
Id1 expression using Western blotting and quantitative RT-PCR. Functional assays were performed to evaluate the role of Id1 in
tumor cell growth, migration and progression. We ﬁnd Id1 expression is upregulated in squamous cell carcinoma when compared
to adenocarcinoma of the lung and that expression of Id1 versus the normal control is variable in NSCLCs. We also note that
Id1 expression in NSCLC cells is largely growth factor dependant and constitutive expression of Id1 in NSCLC cells signiﬁcantly
increases tumor cell migration without aﬀecting cell proliferation. We conclude that Id1, as a mediator of tumor cell migration,
may be an indicator of aggressive potential in nonsmall-cell lung cancers.
1.Introduction
Lung cancer is the most common cause of cancer deaths in
the world with over one million new cases diagnosed per
year [1, 2]. Nonsmall cell lung cancer (NSCLC) accounts
for approximately 80% of all lung cancers and is comprised
predominantly of adenocarcinomas and squamous cell car-
cinomas [3]. The major form of curative treatment for
NSCLC is surgical resection at an early stage of the disease
since systemic therapies for advanced lung cancer show poor
objective response rates [4, 5]. Furthermore, evaluating the
availablebiomarkersforNSCLCmaypredicttumorresponse
to systemic therapy.
Id1 is a member of the helix-loop-helix (HLH) family
of transcriptional regulatory proteins which consist of four
members, Id1 through Id4 [6]. Of all the Id genes, Id1
has been most closely linked to tumorigenesis since it
has been shown to regulate cellular senescence, cellular
proliferation, and cell survival [7–10] and has been found
to be highly expressed in several human cancers [11–22].
Despite compelling data suggesting a role for Id genes in the
development and progression of a large number of human
cancers [22], the role of Id genes in lung cancers has not been
extensively evaluated to date. A recent study identiﬁed Id1 as
being diﬀerentially expressed in small cell lung cancers [23]
and went on to ﬁnd elevated Id1 gene expression in tumor
cells versus matched control tissues; however, no assessments
were made for Id1 in nonsmall cell lung cancers.
Here, we seek to deﬁne the diagnostic signiﬁcance of Id1
expression in NSCLCs by exploring the expression patterns
for Id1 in primary human tumors and matched normal
tissues. We also seek to determine the functional signiﬁcance
of Id1 expression in NSCLC development and progression
using in vitro model systems for tumor cell growth and2 Journal of Oncology
migration using lentiviral-mediated constitutively expressed
Id1. We identify a wide range of Id1 expression patterns
in NSCLCs without any notable association of expression
level with tumor staging or outcome; however, we do note
signiﬁcant eﬀects of Id1 expression on tumor cell migration
in vitro. We conclude that Id1 regulates tumor cell migration
in NSCLC cells which suggests a functional role in tumor
progression for this aggressive form of lung cancer.
2.MaterialsandMethods
2.1. Cell Lines and Cell Culture. Nonsmall cell lung cancer
cell (NSCLC) lines were obtained from American Type
Culture Collection (ATCC, Manassas, VA). The cells H460,
A427, H520, H23, H1915, H1299, and U1752 were cultured
inRPMI1640(Invitrogen,Carlsbad,CA)supplementedwith
10% heat inactivated fetal bovine serum (FBS) from Hyclone
(Logan, Utah) and 5% Pennicilin-Streptomycin (Invitrogen)
at 37
◦C. Lentivirus was produced in HEK 293T cells using
previously described protocols [24]. All lentiviral constructs
werelabeledwithGFPandproducedinHEK293Tcells.Viral
supernatant was collected for 3 days and concentrated using
Centricon centrifugation. Viral titer was measured using
Flow Cytometry and evaluating GFP expression. Cells were
then transduced as mentioned in the manuscript at an MOI
of 10. H23 cells were infected by adding viral particles to
media along with polybrene at 6mg/mL and incubating the
cells for 6 hours. Fresh media were added and the cells were
allowed to recover and grow for a week before they were used
for any experiments.
2.2.WesternBlotAnalysis. Cells werewashedwithphosphate
buﬀered saline (PBS) and pelleted after trypsinization. Pro-
teins were extracted from whole cell lysate by resuspending
cell pellets in lysis buﬀer (250mM NaCL, 50mM Tris-Hcl,
5mM EDTA and 0.1% NP-40) including protease inhibitors
obtained commercially (Sigma) and 1mM PMSF. Protein
concentration was measured using the protein assay kit (Bio-
Rad, Hercules, CA). 20ug of protein samples were sep-
arated using 15% sodium dodecylsulphate-polyacrylamide
gel (SDS-PAGE) commercially available from Bio-Rad for
electrophoresis and transferred to Immobilon-P a nylon
membrane (Immobilon, Bradford, MA). The membrane
was then incubated with primary antibody for 1 hour at
room temperature against Id-1(sc-488) and B-actin (sc-
1616) (Santa Cruz Biotechnology, Santa Cruz, CA). After
washing with TNET (200mM Tris-Hcl, 50mM EDTA, 1M
NaCl, 0.5% Tween) the membrane was incubated with
secondary antibody against rabbit IgG and the signals
were visualized using ECL Western Blot Analysis system
(Amersham, Piscataway, NJ).
2.3. MTS Proliferation Assay. A colorimetric-based kit One
Solution Cell proliferation Assay composed of the novel
tetrazolium compound, 3-(4,5-dimethylthiazol-2yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium,
inner salt (MTS) (Promega Corporation, 2800 Woods
Hollow Rd, Madison, WI), was used to quantify cell
proliferation following the manufacturer’s protocol. H23,
nonsmall cell lung cancer cells were plated in triplicate with
serial dilutions for the standard curve while a ﬁxed number
of cells were plated and analyzed for proliferation at various
time points.
The MTS reagent was added to cell media and incubated
for1–4hoursandtheabsorbancemeasuredina96-wellplate
reader at 490nm. The assay was repeated a minimum of 3
times for each sample.
2.4. Scratch/Migration Assays. H23 cells were plated in 12-
wellplatesinduplicateatapproximately85%conﬂuencyand
allowed to grow overnight. The following day a scratch was
made through the center of each well using a 200µL pipet
tip. The cells were washed with PBS and fresh media were
added to remove any loose cells. Photographs were taken of
the initial scratch and then at regular intervals in order to
measure the migration of cells into the scratched area. This
assay was performed in triplicate.
A transwell migration assay was performed using Falcon
cell culture inserts (Becton Dickinson Labware, Franklin
Lakes, NJ). Brieﬂy, 3 ×104 H23 cells were plated in a 24-well
cell culture insert in 0.5mL of 1% FBS-RPMI media. Inserts
were then placed in 0.75mL of 10% FBS-RPMI media in the
well and allowed to grow for 48 hours. The inserts with H23
cells were then ﬁxed in 70% ethanol for 3 minutes, rinsed
in distilled water, stained in hematoxylene for a minute and
then washed again in tap water. Cells within the insert were
scraped out with a Q-tip such that only the cells that have
migrated through the pores of the insert would remain ﬁxed
and stained. Finally, the inserts were cut out and placed on
glass slides with ﬁxed by cover slips. Five ﬁelds were selected
and counted at high power for an average number of cells in
each insert.
2.5. Human Lung Tissue Samples. Snap-frozen human lung
tissues were obtained from the Department of Pathology
at Johns Hopkins Hospital under institutionally-approved
protocols. A total of 45 tissues that were received in two
batches. The ﬁrst batch of 30 lung tissues contained tumor
with adjacent normal (noncancerous) tissue from each
patient. The second batch of 15 samples had tumor tissue
only from each patient. Annotated data for each tissue
specimen include the tumor type, the gender and age of the
patient,thesmokingstatusofthepatient,andthestageofthe
disease at the time of diagnosis including the involvement of
lymph nodes.
2.6. Quantitative RT-PCR. T o t a lR N Aw a se x t r a c t e df r o m
the lung tissue samples using the RNEasy mini kit (Qiagen,
Turnberry Lane, Valencia, CA). 5ug RNA was reverse
transcribed using SuperScript
TM 11 reverse transcriptase
with Oligo (dT) (Invitrogen, Carlsbad, CA). Primers for
human Id1 included (Fwd: CACCCTCAACGGCGAGAT,
Rev: CCACAGAGCACGTAATTCCTC). The sequence for
the speciﬁc Id1 probe was 56-FAM/ACGGCCGAGGC-
GGCATGCGT/36-TAM. Quantitative Real-time Polymerase
chain Reaction (QRT-PCR) was performed using 10ngJournal of Oncology 3
of RNA from each patient sample. TaqMan 2X master
mixture (Applied Biosystem) was used in a total volume
of 20uL reaction mixture. Human B-actin was used as the
control with commercially available primers and probes
(Applied Biosystems). Reaction conditions were 2 minutes
at 50
◦C ,1 0m i n u t e sa t9 5
◦C, 40 cycles of 15seconds at
95
◦C, and 45seconds at 60
◦C. Every sample was repeated in
triplicate and results were conﬁrmed by repeating the entire
experiment at least twice.
2.7. Statistical Methods. For human lung cancer tissues with
paired normal tissue, we tested the ﬁrst hypothesis of mean
diﬀerences in Id1 expression levels between cancerous and
matched normal tissue by tissue type. Additionally, we
examined the eﬀect of patient characteristics, gender (male
versus female) smoking status (smoker versus nonsmoker),
and the clinical outcome of alive versus dead as of 2001 on
mean diﬀerences in Id1 expression levels between cancerous
and matched normal tissue using a linear model with
generalizedestimatingequationstoaccountforthematching
of samples within a patient. For human lung tissues with
only cancer tissues (unmatched samples) we tested the
hypothesis of mean diﬀerences in Id1 expression levels
between adenocarcinoma versus squamous cell carcinomas.
We used a normal tissue that we purchased from Clonetech
and tested the hypothesis that there is a diﬀerence in Id1
levels between the cancerous and normal tissues.
3. Results
3.1. Id1 Expression in Nonsmall Cell Lung Cancer Cells
(NSCLC) Is Growth Factor-Dependent. I no r d e rt oe x p l o r e
Id1 protein levels in nonsmall cell lung cancers, a panel
of NSCLC cell lines was analyzed for Id1 expression by
Western blotting and Id1 transcript level was determined by
quantitative RT-PCR. We found variable expression of Id1
in the tumor cell lines evaluated with highest expression in
H520, H1299, U1752, and H460 (Figure 1(a)). The lowest
levelofexpressionwasfoundintheadenocarcinomacellline,
H23 (Figure 1(a)). Since Id1 gene expression is notorious for
being serum-responsive [25–27], we evaluated the eﬀects of
varying serum concentrations on NSCLC expression of Id1.
WefoundthatthevastmajorityofNSCLCcelllinesevaluated
expressed low levels of Id1 in media containing 1% serum
and that Id1 was signiﬁcantly elevated in cells cultured in
media with 10% serum suggesting that Id1 expression in
NSCLC is growth factor-responsive (Figure 1(b)). Interest-
ingly, while H1299 cells expressed increasing amounts of Id1
as a function of increasing serum concentrations, the H23
adenocarcinoma cell line failed to demonstrate signiﬁcant
Id1 induction following serum exposure (Figure 1(c)).
3.2. Id1 Promotes Migration of Nonsmall Cell Lung Cancer
Cells. In order to assess the function of Id1 in NSCLC
cells we selected the H23 cell line to ectopically express
Id1 and evaluate the biologic consequences. H23 cells were
transduced with Id1 using a bicistronic lentiviral expression
system also encoding GFP and a GFP lentiviral vector as
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Figure 1: Id1 expression is variable in NSCLC cell lines and
responsive to serum induction. (a) Western blot analysis of Id1
expression in nonsmall cell lung cancer (NSCLC) cell lines. Variable
expression of Id1 is noted in NSCLCs with elevated expression seen
in H520, H1299, U1752, and H460 cells. Mel-3 is used as a positive
control for Id1 and Mel-4 is used as a negative control for Id1. (b)
Westerm blot analysis of Id1 expression in NSCLC in response to
1% and 10% of serum concentration. (c) Western blot analysis of
Id1 expression in H1299 and H23 NSCLC cell lines in response to
1%, 5%, and 10% serum. Mel-3 is used as a positive control for Id1.
ac o n t r o la sp r e v i o u s l yr e p o r t e d[ 24, 28]. H23 cells were
eﬃciently transduced by the lentiviral vectors as assessed
by GFP expression (Figure 2(a)) and Id1 expression was
eﬃciently induced as demonstrated by Western blotting for
Id1 (Figure 2(b)).
In order to evaluate the inﬂuence of Id1 expression on
NSCLC tumor cell growth, normal H23 cells (NI) and H23
cells transduced with lentivirus expressing GFP alone (GFP)
or GFP-Id1 (Id1) were evaluated in an MTS proliferation
assay. Cells expressing Id1 did not demonstrate any notable
change in growth versus GFP-expressing cells, and both
transduced cell lines were found to grow more slowly than
the noninfected tumor cells (Figure 2(c)). Since Id1 has
been implicated in promoting tumor cell migration and
invasion [29–31], cellular migration was evaluated in H23
cells expressing Id1 in both a scratch assay and a transwell
migration assay. We notably found a signiﬁcant increase
in cellular migration in both a transwell migration assay
(Figures 2(d) and 2(e)) and a scratch assay (data not shown)
with a greater than 6-fold increase in migration seen in H23-
Id1 cells.4 Journal of Oncology
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Figure 2: Exogenous expression of Id1 in NSCLC cells promotes tumor cell migration but not tumor cell growth. (a) Expression of vector alone
(GFP) and Id1 (Id1) in H23 cells infected with a GFP-expressing lentiviral vector. (b) Western blot analysis of Id1 expression in H23 cells
following transduction by lentivirus expressing Id1 (H23 Id1), GFP alone (H23 GFP), or noninfected cells (H23NI). Mel-3 is used as a
positive control for Id1. (c) H23 NSCLC cell growth following transduction with lentivirus expressing Id1 (Id1), GFP alone (GFP), and
noninfected cells (NI). Error bars indicate standard deviation. (d) Boyden chamber migration assay for H23 NSCLC cells expressing GFP
alone, Id1, or noninfected cells. (e) Quantiﬁcation of Boyden chamber assay depicted in (d).
3.3. Id1 Is Variably Expressed in Nonsmall Cell Lung Cancers.
In order to evaluate the in vivo expression of Id1 in NSCLC
we prepared mRNA from primary human tumors and
matched normal tissues and assessed Id1 expression using
quantitative RT-PCR. For 30 specimens, each tumor speci-
men was provided with adjacent normal lung tissue and Id1
expression was compared between tumor and normal tissue
fromeachpatient(Figures3(a)–3(c)).Sincethevastmajority
of specimens were lung adenocarcinomas (AD) or squamous
cell carcinomas (SCC), tumors were sorted based on this
distinction to further evaluate Id1 expression trends. Among
the 14 lung adenocarcinomas, we observed elevated Id1
expression in tumor specimens versus normal lung in 5 cases
with no notable association with tumor stage at the time of
diagnosis (Figure 3(a)). We also noted overall signiﬁcantly
lower Id1 expression as compared to matched normal tissue
(P = .02) in adenocarcinomas (Table 1). Similarly, among
the 9 matched squamous cell carcinomas evaluated elevated,
Id1 expression was found to be elevated in tumor specimens
versus normal lung in 5 cases with no notable association
with tumor stage at the time of diagnosis (Figure 3(b)). In
contrast, for the 9 matched squamous cell carcinomas of
the lung, we observed overall greater average Id1 expression
as compared to matched normal tissue, although these
diﬀerences were not statistically signiﬁcant (P = .65).
Furthermore, among the 7 other matched lung cancer tissue
types (2 carcinoid, 1 carcinoma, 1 small cell, 1 small and
large cell, 1 nonsmall cell, and 1 bronchoalveolar) mean Id1Journal of Oncology 5
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Figure 3: (a) Quantiﬁcation of Id1 expression by qRT-PCR in primary lung adenocarcinomas versus matched normal tissues. (b)
Quantiﬁcation of Id1 expression by qRT-PCR in primary lung squamous cell carcinomas versus matched normal tissues. (c) Quantiﬁcation
of Id1 expression by qRT-PCR in primary NSCLCs (not adenocarcinoma or squamous cell carcinoma) versus matched normal tissues. (d)
Quantiﬁcation of Id1 expression by qRT-PCR in primary lung adenocarcinomas without matched normal tissues. (e) Quantiﬁcation of Id1
expression by qRT-PCR in primary lung squamous cell carcinomas without matched normal tissues. (f) Quantiﬁcation of Id1 expression by
qRT-PCR in primary NSCLCs (not adenocarcinoma or squamous cell carcinoma) without matched normal tissues.
expression was signiﬁcantly lower in tumor as compared to
matched normal tissue (P = .007) (Figure 3(c)).
Comparison of Id1 expression in unmatched lung ade-
nocarcinomas and squamous cell carcinomas showed no
statistically signiﬁcant diﬀerences in mean Id1 expression
(Figures 3(d)–3(e), Table 2), with variable expression in
tumor specimens relative to a normal lung control. For
the 4 unmatched “other” NSCLC tumors, only 1 tumor
demonstrated signiﬁcantly elevated Id1 expression with 20-
fold increased Id1 expression versus the normal control
noted in a carcinoid tumor (Figure 3(f)).
Boxplot analyses for all specimens did not demonstrate
signiﬁcant diﬀerences between either lung adenocarcinomas
or squamous cell carcinomas and normal tissues (Figures
4(a)and4(b));however,statisticallyincreasedId1expression
was nearly achieved for squamous cell carcinomas versus
adenocarcinomas (Figure 4(c))( P = .0579) (Tables 1 and 2).
Because of the greater number of samples available from
the matched tissues, we further examined the eﬀect of
other patient characteristics, gender (male versus female),
smoking status (smoker versus nonsmoker), and patient
o u t c o m e( a l i v ev e r s u sd e a d ) ,o nm e a nd i ﬀerences in Id1
expression levels with respect to each tissue type, adeno-
carcinoma, squamous cell carcinoma, and other (Table 3).
No statistically signiﬁcant mean Id1 expression diﬀerences
were observed for each comparison, although increased
Id1 expression in adenocarcinoma patients who reported
smoking was nearly signiﬁcant (P = .06) as compared to
reported nonsmoker adenocarcinoma patients.
4. Discussion
Id proteins have been shown to be highly expressed in a
large number of cancers (reviewed in [22]). In several of
these cancer types, overexpression of Id1 is associated with
an aggressive phenotype and poor clinical outcome [14–
16, 32]. Functional studies have demonstrated that Id1 is
able to promote cell proliferation [33], delay senescence in
primary human cells [7, 9], and promote cell migration [34]
and the metastatic phenotype of cancers [35, 36]. While
Id proteins, and Id1 in particular, have been found to be
upregulated in a large number of tumors, studies of Id6 Journal of Oncology
Table 1: Id1 expression level in primary human lung tissues versus adjacent normal tissue. Expression level is average qRT-PCR signal for
Id1/average signal for GAPDH ×103.
Tissue type No. samples Mean (SE)∗ Id1 expression 95% C.I P-value
+
Normal Tumor
Adenocarcinoma 14 2.55 (0.07) 2.14 (0.14) (0.09, 0.74) .02
Squamous Cell Carcinoma 9 2.62 (0.05) 2.68 (0.12) (−0.36, 0.24) .65
Others 7 2.58 (0.07) 2.03 (0.16) (0.21, 0.90) .007
∗Natural log transformed mean and standard error (SE); +P-value based on two-sided two-sample t-test of hypothesis of no mean diﬀerence between tissue
types.
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Figure 4: Boxplots comparing Id1 expression levels for (a) squamous cell carcinomas of the lung versus matched control tissue, (b)
adenocarcinomas of the lung versus matched control tissue, and (c) squamous cell carcinomas of the lung versus adenocarcinomas of the
lung.
genes in lung cancer have been limited to date with a single
previous study evaluating Id gene expression in small cell
lung cancers focused on Id genes as biomarkers in these
tumors rather than the functional eﬀects of Id genes in this
malignancy [23]. Here we have evaluated the expression
of the helix-loop-helix transcription factor, Id1, in human
nonsmall cell lung cancers and its functional signiﬁcance in
these tumors. Our study indicates that although signiﬁcant
Id1 expression is seen in NSCLCs, no particular trends are
noted in comparison to matched normal human tissues.
Interestingly, our study indicates that patients with lung
adenocarcinomas express lower levels of Id1 when comparedJournal of Oncology 7
Table 2: Id1 expression level in primary human lung adenocarcinomas versus squamous cell carcinomas. Expression level is average qRT-
PCR signal for Id1/average signal for GAPDH × 103 Primary NSCLC tumor specimens were evaluated for Id1 expression by qRT-PCR and
expression levels for SCCs and AdenoCAs were compared.
Tissue type Mean (SE)∗ Id1 expression Tissue type Mean (SE)∗ Id1 expression P-value+
Adenocarcinoma 2.76 (0.16) Squamous Cell Carcinoma 3.01 (0.22) .41
∗Natural log transformed mean and standard error (SE); +P-value based on two-sided two-sample t-test of hypothesis of no mean diﬀerence between tissue
types.
Table 3: Covariate analysis of Id1 expression in NSCLCs and its association with gender, smoking and patient clinical status.
Gender Smoke Alive
Male (s.e) Female (SE) P-value Nosmoke Smoke P-value Death Alive P-value
Adeno 2.48 (0.15) 2.30 (0.09) .32 2.14 (0.00) 2.32(0.10) .06 2.44 (0.11) 2.31 (0.16) .38
Squamous 2.68 (0.08) 2.60 (0.08) .45 2.74 (0.00) 2.66(0.06) .21 2.63 (0.07) 2.66 (0.10) .80
Others 2.39 (0.08) 2.24 (0.15) .36 2.44 (0.30) 2.25(0.11) .27 2.24 (0.19) 2.35 (0.08) .58
to patients with squamous cell carcinomas although neither
level is consistently above that expressed in surrounding
normal tissues.
Our in vitro analysis of Id1 function in NSCLC cell
lines indicates that although most tumor cells expressed a
high level of Id1 when cultured in media containing 10%
serum, most Id1 expression in these tumors is growth factor
dependent and not constitutive. Of note, H23 adenocarci-
noma cells were shown to express low levels of Id1 even
when grown in media containing increased levels of serum.
We took advantage of this attribute of this particular cell
line to ectopically express Id1 and evaluate its functional
role in NSCLC. Our study demonstrated that although the
growthrateofcellsexpressingectopicallytransducedId1was
not signiﬁcantly altered by Id1 expression, Id1-transduced
cells demonstrated a signiﬁcantly increased rate of migration
when compared to cells that were noninfected or expressed
only GFP.
Studies of Id1 expression in primary human NSCLCs
demonstrated lower Id1 expression in adenocarcinomas of
the lung when compared to squamous cell carcinomas
with variable expression compared to matched normal lung
tissues.
Given the above data, we hypothesize that deregulated
expression of Id1 in NSCLCs may be associated with an
increased rate of cell migration and therefore contribute
to metastasis in patients with poor outcome. While the
prognosis for the vast majority of NSCLC patients is
extremely poor, we note that the primary human tumors
evaluated in this study segregated into groups with elevated
tumor Id1 expression versus normal tissue and decreased
tumor expression versus normal tissue. We therefore suggest
that Id1 expression in NSCLCs may allow for distinction of
NSCLC tumor subtypes which may be speciﬁcally responsive
to particular forms of therapy targeting Id1. Given the
universally poor prognosis of NSCLCs and the lack of an
eﬀective therapy for advanced disease, the results of this
pilot study should pave the way for larger-scale evaluation
of Id1 in NSCLCs to assess its true signiﬁcance in this
malignancy.
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